These data, together with the fact that CRL4 is activated through neddylation in the DDR pathway, suggest a potential strategy for anti-tumor therapy, through the inhibition of CRL4 using MLN4924, an inhibitor of the NEDD8-activating enzyme that can effectively inhibit the neddylation of the Cullin family proteins (62). Here, IL17RB is linked to neoplasm.